Designing molecules that matter is driven by the combined power of accurate computational methods and human collaboration.
Schrödinger has partnered with Lilly TuneLab™, a platform launched by Eli Lilly and Company designed to accelerate drug discovery and development by providing access to advanced AI capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s industry-leading enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.
LiveDesign is a flexible, cloud-native working environment for your entire discovery team, spanning both small and large molecule research — all in a single interface.
TuneLab is a collaborative platform created to offer access to AI/ML tools leveraging Lilly’s own drug discovery models.
“Schrödinger has a track record of successfully leveraging LiveDesign’s array of enterprise features and physics-based and AI/ML methods to advance our therapeutics portfolio, and we look forward to building on that success with TuneLab.”
“We launched TuneLab to provide to biotech partners the power of our collective data. We are pleased to be partnering with Schrödinger to provide biotechs access to TuneLab, given their leadership in computational methods and digital drug design.”
“We are pleased that LiveDesign will be a priority platform partner for TuneLab workflows, reflecting the demand for a unified enterprise informatics solution that democratizes access to AI models, physics-based calculations, and experimental data across discovery teams.”
